US acquires 600,000 new doses of GSK-Vir COVID drug

Tuesday, 11. January 2022 13:33

The United States government reached a deal to buy 600,000 doses of the antibody COVID-19 treatment developed by GlaxoSmithKline and Vir Biotechnology, the two companies confirmed on Tuesday.

The batch will be delivered in the first quarter of this year, the statement added, bringing the total number of the GSK-Vir doses secured by countries worldwide to 1.7 million.

GSK's stock stood unchanged, while Vir added 2.39% in the premarket trading following the news.

Related Links: Vir Biotechnology Inc.GlaxoSmithKline PLC
Baha Breaking News (BBN) / ND